A Phase I/II Trial of Bnc105P with Everolimus in Metastatic Renal Cell Carcinoma (Mrcc): Results of the Randomized Phase Ii Disruptor-1 Trial

Autor:	Arun Azad, Jose Iglesias, Timothy Breen, Brian A. Costello, Noah M. Hahn, Elizabeth E. Doolin, Guru Sonpavde, Sumanta K. Pal, J. Sarantopolous, Christopher Sweeney, Thomas E. Hutson, Stephen Lane Richey, Richard C. Lauer, Ravindran Kanesvaran, J. Simpson, Gabriel Kremmidiotis, David C. Bibby, Harry A. Drabkin, Shailender Bhatia
Rok vydání:	2014
Předmět:	South carolina medicine.medical_specialty Everolimus Tumor necrosis factors business.industry General surgery Complete remission Cancer Hematology medicine.disease Surgery Phase i ii Oncology Renal cell carcinoma Health science medicine business medicine.drug
Zdroj:	Annals of Oncology. 25:iv283
ISSN:	0923-7534
DOI:	10.1093/annonc/mdu337.8
Popis:	1 City of Hope Medical Center, Duarte, CA, 2 BC Cancer Agency, Vancouver, BC, 3 Univ. of Washington, Seattle, WA, 4 Medical College of South Carolina, Charleston, SC, 5 Mayo Clinic, Rochester, MN, 6 Univ.of Texas Health Science Center, San Antonio, TX, 7 Singapore National Cancer Center, 8 Univ. of New Mexico Cancer Ctr, Albuquerque, NM, 9 Dana Farber Cancer Center, Boston, MA, 10 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, 11 Deke-Slayton Cancer Ctr., Webster, TX, 12 Texas Oncology, Fort Worth, TX, 13 Hoosier Cancer Research Network, Indianapolis, IN, 14 Bionomics, Thebarton, SA, Australia, 15 bioCSL, Melbourne, Australia, 16 Charles A. Sammons Cancer Center, Baylor Univ.Medical Center, Dallas, TX
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d0e0fc4af6346830e4148220ceaa33c7 https://doi.org/10.1093/annonc/mdu337.8 Zobrazit plný text záznamu